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There have been great advances in the therapy of cancer and 
leukemia. But it is still true that many neoplastic diseases 
are difficult to treat. Especially, there is often no way to treat 
difficult ones such as hormone-insensitive breast carcinoma 
and prostate carcinoma, pancreatic carcinoma, cholangio-
carcinoma, and multiple myeloma.
NF-kappa B is a transcription factor that enhance expres-
sions of many inflammatory cytokines. It has a role on 
activation of immunity and on tissue stability. But excess 
activation of NF-kappa B especially in macrophages often 
causes inflammation and cancer. Around 2000, dehydroxy-
methylepoxyquinomicin (DHMEQ, fig. 1) was discovered 
by Umezawa as an inhibitor of NF-kappa B [1].
It was shown to be a very specific inhibitor that directly 
binds to and inactivates NF-kappa B components [2]. Until 
now DHMEQ has been used by many scientists in the world 
to suppress animal models of cancer and inflammation (3). 
Especially it suppressed difficult cancer models such as 
hormone-insensitive breast cancer and prostate cancer, and 
multiple myeloma.
All the results in figure 2 were published in various interna-
tional journals including the top class ones such as Cancer 
Research and Blood. Moreover, no toxicity has been report-
ed ever. Chemicals are usually injected into the peritoneal 
cavity in rodent experiments because of the easy technique. 
Later, Umezawa suggested that intraperitoneal (IP) admin-
istration itself is important for the effectiveness and safety of 
DHMEQ [3–5], as shown in figure 3.
DHMEQ does not go to systemic circulation. DHMEQ in-
hibits inflammatory reaction in human peritoneal cells [6].
Gantsev and Umezawa began collaboration on the clinical 
use of DHMEQ IP therapy in Bashkortostan State Medical 
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Figure 1. Structure of DHMEQ, an NF-kappa B inhibitor
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University in 2013. Kickoff Meeting with the President of 
Bashkortostan State was broadcasted in TV. PeritonTreat 
Ltd was founded in Ufa for the development of DHMEQ IP 
therapy. Since then, marked progress has been made. For ex-
ample, in the occasion of BRICS Summit in Ufa in 2015, we 
organized Satellite Symposium of BRICS Summit entitled 
“Development of novel drug DHMEQ in BRICS countries”. 
Now we are very close to the clinical use of DHMEQ IP 
therapy on difficult cancer. It is now an international project 
including Russia, Japan, and Kazakhstan.
Anti-PD-1 antibody and anti-CTLA-4 antibody therapies 
are effective on melanoma and other cancers. However, thy 
say, anti-PD-1 therapy is effective on 20–30 % of even mel-
anoma. The rest 70–80 % of patients are non-responding. 
These therapies are immune-activation therapy. Instead, 
DHMEQ IP therapy is an immunosuppressive therapy. It 
may be effective on the patients who are resistant to im-
mune-activation therapy.
DHMEQ has been used in many laboratories in the world 
to show effectiveness to various cancer and inflammation 
animals. The therapy is extremely safe because of the IP 
therapy. If it can be used for patients, there appears a good 
possibility to save many patients suffering cancer and severe 
inflammation.
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Figure 3. Target of DHMEQ is likely to be NF-kappa B of peritoneal cells. IP administration of DHMEQ 
lowers inflammatory cytokines in the blood vessels to inhibit local inflammation and cancer
Figure 2. Suppression of various inflammatory and neoplastic disease models in animal experiments by 
intraperitoneal administration of DHMEQ
